These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1872339)

  • 1. CA 125 regression: a model for epithelial ovarian cancer response.
    Buller RE; Berman ML; Bloss JD; Manetta A; DiSaia PJ
    Am J Obstet Gynecol; 1991 Aug; 165(2):360-7. PubMed ID: 1872339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol.
    Pearl ML; Yashar CM; Johnston CM; Reynolds RK; Roberts JA
    Gynecol Oncol; 1994 Jun; 53(3):339-43. PubMed ID: 7911444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA 125 half-life in ovarian cancer: a multivariate survival analysis.
    Yedema CA; Kenemans P; Voorhorst F; Bon G; Schijf C; Beex L; Verstraeten A; Hilgers J; Vermorken J
    Br J Cancer; 1993 Jun; 67(6):1361-7. PubMed ID: 8512822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in CA125 concentration in ovarian cancer patients during the remission state--mean attenuating curve and the effectiveness of surgery and chemotherapy].
    Kawai M; Inagaki S; Yamashita H; Imaizumi H; Kakihara M; Arii Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):537-42. PubMed ID: 2474041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
    Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
    Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
    Wils JA
    Oncology; 1990; 47(2):115-20. PubMed ID: 2107480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of clinical course and recurrence of human ovarian cancer by several serum tumor markers.
    Kikuchi Y; Kita T; Iwano I; Kuki E; Oomori K; Kizawa I
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):69-76. PubMed ID: 2926196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s.
    Buller RE; Vasilev S; DiSaia PJ
    Am J Obstet Gynecol; 1996 Apr; 174(4):1241-53; discussion 1253-4. PubMed ID: 8623852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Tsukada Y; Emrich LJ
    J Clin Oncol; 1988 Jun; 6(6):983-9. PubMed ID: 3373267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
    Yan X; An N; Jiang GQ; Gao M; Gao YN
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):298-301. PubMed ID: 18788637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
    Riedinger JM; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
    Bull Cancer; 1996 Aug; 83(8):654-63. PubMed ID: 8869046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
    Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
    Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
    Lukácskó I; Hernádi Z; Sápy T; Borsos A
    Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian epithelial tumors of low malignant potential.
    Chien RT; Rettenmaier MA; Micha JP; DiSaia PJ
    Surg Gynecol Obstet; 1989 Aug; 169(2):143-6. PubMed ID: 2756462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of intervention surgery in stage III-IV epithelial ovarian carcinoma.
    Hoogland H; Blijham G; Bron H; Eekhout A; van Geuns H; Haest J; Huiskes H; Kornman J; de Koning Gans H; Lalisang F
    Prog Clin Biol Res; 1985; 201():213-5. PubMed ID: 3841592
    [No Abstract]   [Full Text] [Related]  

  • 19. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
    Hunter VJ; Daly L; Helms M; Soper JT; Berchuck A; Clarke-Pearson DL; Bast RC
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1164-7. PubMed ID: 2171337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
    Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.